Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 12/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104200 | 0.85 | SCN10A (0.43) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL5110664 | 0.85 | SCN10A (0.48) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL4158718 | 0.83 | SCN10A (0.57) | SCN10AKDM4ELMNAHSD17B10TAAR1 | |
| SCHEMBL15157108 | 0.83 | SCN10A (0.57) | SCN10AKDM4ELMNAHSD17B10TAAR1 | |
| SCHEMBL15172655 | 0.83 | SCN10A (0.57) | SCN10AKDM4ELMNAHSD17B10TAAR1 | |
| SCHEMBL5100116 | 0.83 | SCN10A (0.58) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL1479636 | 0.82 | LMNA (0.42) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL5104456 | 0.82 | LMNA (0.42) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL580393 | 0.82 | LMNA (0.42) | SCN10AHRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL5104217 | 0.82 | SCN10A (0.39) | SCN10AHRH4IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-06-05 | — | — | US | disclosed |
| US-7326791-B2 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | SCN10A 1465/4885HRH4 589/4885KDM4E 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.